rebound covid with symptoms; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (rebound covid with symptoms) in a 37-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Previously administered products included for Product used for unknown indication: Pfizer/BioNTech (Dose number 3) on 06-Nov-2021. Past adverse reactions to the above products included No adverse event with Pfizer/BioNTech. Concurrent medical conditions included Obesity and Allergy. Concomitant products included SERTRALINE for an unknown indication.   On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (Oral) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (rebound covid with symptoms). At the time of the report, COVID-19 (rebound covid with symptoms) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 24-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that the patient was taking any other medications or products within 2 weeks of starting COVID-19 treatment. Patient stated that symptoms were improved after taking Paxlovid Device Date was reported as 24-May-2022 Patient took Pfizer / BioNTech as Dose 3 on 6-Nov-2021  No treatment medications were reported  Company comment: This spontaneous case concerns a 37-year-old, male patient with underlying medical condition of obesity who experienced the unexpected, non-serious adverse event of special interest of COVID-19, which occurred approximately 13months after receiving a dose of mRNA-1273 vaccine as second dose of COVID-19 vaccine. It should be noted that the patient received a dose of different COVID-19 vaccine (Pfizer/Biontech) 7 months and 17 days after the second dose of mRNA1273.  The patient was diagnosed with COVID-19 and started Nirmatrelvir, Ritonavir (Paxlovid) on 05/12/2022 and completed the course for 5 days. The patient claims that the symptoms improved and he tested negative on a rapid test for COVID-19 taken at an unknown date. 7 days after treatment the patient reported return of symptoms and tested positive again on a rapid test for COVID-19. The patient's underlying medical condition of obesity may be considered as a risk factor for the event COVID-19. The benefit-risk relationship of mRNA-1273 is not affected by this report. Sender's Comments: This spontaneous case concerns a 37-year-old, male patient with underlying medical condition of obesity who experienced the unexpected, non-serious adverse event of special interest of COVID-19, which occurred approximately 13months after receiving a dose of mRNA-1273 vaccine as second dose of COVID-19 vaccine. It should be noted that the patient received a dose of different COVID-19 vaccine (Pfizer/Biontech) 7 months and 17 days after the second dose of mRNA1273.  The patient was diagnosed with COVID-19 and started Nirmatrelvir, Ritonavir (Paxlovid) on 05/12/2022 and completed the course for 5 days. The patient claims that the symptoms improved and he tested negative on a rapid test for COVID-19 taken at an unknown date. 7 days after treatment the patient reported return of symptoms and tested positive again on a rapid test for COVID-19. The patient's underlying medical condition of obesity may be considered as a risk factor for the event COVID-19. The benefit-risk relationship of mRNA-1273 is not affected by this report.